Trial Profile
Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Acronyms PK-e3i trial
- 04 Feb 2021 Results of Population PK-PD modelling of circulating lymphocyte dynamics in chronic lymphocytic leukemia patients using data from this trial published in the Clinical Pharmacology and Therapeutics
- 24 Dec 2020 Status changed from discontinued to completed.
- 06 Aug 2020 Status changed from recruiting to discontinued.